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Abstract: Extracellular vesicles (EVs) shuttle microRNA (miRNA) throughout the circulation and 
are believed to represent a fingerprint of the releasing cell. We isolated and characterized serum 
EVs of breast tumour-bearing animals, breast cancer (BC) patients, and healthy controls. EVs were 
characterized using transmission electron microscopy (TEM), protein quantification, western 
blotting, and nanoparticle tracking analysis (NTA). Absolute quantitative (AQ)-PCR was employed 
to analyse EV-miR-451a expression. Isolated EVs had the appropriate morphology and size. Patient 
sera contained significantly more EVs than did healthy controls. In tumour-bearing animals, a 
correlation between serum EV number and tumour burden was observed. There was no significant 
relationship between EV protein yield and EV quantity determined by NTA, highlighting the 
requirement for direct quantification. Using AQ-PCR to relate miRNA copy number to EV yield, a 
significant increase in miRNA-451a copies/EV was detected in BC patient sera, suggesting potential 
as a novel biomarker of breast cancer. 
Keywords: breast cancer; extracellular vesicles; exosomes; microRNA; biomarker; EV 
characterization 
 
1. Introduction 
Initially deemed a mechanism of cellular waste disposal, extracellular vesicles (EVs) secreted by 
cells are now known to encapsulate a variety of biomolecules thought to be reflective of the cell from 
which they are released [1]. As such, they hold significant potential as circulating biomarkers of 
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disease, with proposed applications in cancer diagnosis, prognostication, and prediction or 
monitoring of response to therapy [1–7]. However, rapid expansion in the field, as evidenced by a 
surge in publications, is not without challenges. There has been a significant amount of conflicting 
evidence in the literature regarding EVs with respect to nomenclature, isolation, characterization, 
quantification, and transparency of reporting standards [8–12]. A myriad of EV purification and 
characterization methods are employed by different research groups, often with poor reporting of 
key experimental parameters. This issue was explored in detail by the EV-TRACK Consortium 
(2017) which paved the way for development of the “EV-METRIC,” with the aim of improving 
completeness of reporting on study methodology going forward [11]. More recently, a further 
update was provided through publication of the Minimal Information for Studies of Extracellular 
Vesicles (MISEV) 2018 guidelines [12]. There is a move to referring to exosomes and other vesicles 
simply as EVs, recognizing the heterogeneity of all isolates, while providing detailed descriptions of 
isolation methods and specific characterization criteria. The universal adoption of this approach 
should increase transparency of reporting and support reliable comparison of data generated by 
different groups, supporting progress to clinical application. 
EVs encapsulate a plethora of potentially clinically relevant biomolecules, including 
microRNAs (miRNAs) [1], which have been at the forefront of breast cancer research in recent 
decades, with innumerable studies attempting to elucidate biomarker potential [13–15]. Despite 
initial promise, circulating miRNAs have yet to be implemented in a clinical setting. The reason for 
this is multifactorial and includes broad variations in starting materials (whole blood, serum, or 
plasma) and extraction methods, and inconsistent use of endogenous controls [13]. As a result of 
this, the body of research on cancer-related miRNAs is contrasting, with conflicting results reported 
for the same miRNA being commonplace, even when evaluated in an identical disease setting [13]. 
Limiting the focus of interest to the miRNA contained in the EV fraction of blood alone may help to 
overcome these challenges. It is imperative, however, that we remain cognizant of these pitfalls, and 
avoid the initial mistakes made in the field of miRNA-oriented biomarker discovery and validation, 
when attempting to expound the clinical relevance of EV-encapsulated miRNAs (EV-miRs). 
There have been a number of initial studies investigating circulating EV-miRNAs as biomarkers 
of breast cancer in recent years [5,16–21]. Although limited by control sample size, one study 
reported elevation of miRNA-101 and miRNA-372 in serum-derived EVs of patients with breast 
cancer (n = 50) compared to healthy controls (n = 12) [5]. The use of EV-miRNAs as a prognostic 
marker for metastatic progression in breast cancer was investigated by Zhou et al., [16], employing 
serum EVs in a murine model of breast cancer and in 38 patients. Significantly elevated EV-miR-105 
levels were detected in patients who went on to develop distant metastases (n = 16) compared to 
those who did not (n = 22). In these studies, like many published at the time, either no quantification 
or indirect quantification of EVs using a protein assay was employed, and so, variable amounts of 
EV template may have been inadvertently included in each group. 
Analysis of plasma EV-miRNAs in breast cancer has also been performed using patient derived 
xenograft (PDX) murine models, breast cancer patients, and healthy controls (n = 16 each) [17]. 
EV-miR-21 and miR-1246 were found to be significantly elevated in the plasma of patients with 
breast cancer compared to healthy controls. For normalization of RT-PCR data, a synthetic 
Caenorhabditis elegans miR-54 (cel-miR-54) RNA oligonucleotide was used as a spike-in control, as no 
robust endogenous controls for exosome/EV-miRNAs exist. While one study reported the use of 
plasma EV-miR-16 as an endogenous control [21], another reported dysregulation of plasma 
EV-miR-16 in patients with breast cancer [18]. In the latter study, miR-484 was employed as an 
endogenous control, along with synthetic cel-miR-39, as miR-484 showed the smallest variation 
between healthy controls and patient samples. However, there was no apparent standardization of 
loading material, and following isolation of EVs using a commercial kit, samples were characterized 
only by the presence of CD63 and absence of Ago2 (usually associated with cell free miRNA) by 
western blot [18]. As a result, data may be impacted through analysis of differing yields of EVs in 
patient samples, thereby impacting the levels of miRNAs detected. The studies outlined provide an 
important proof-of-principle, despite their limitations in size and scope. 
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In the largest study published to date, Stevic et al. [19] analysed the microRNA profiles of 
serum EVs from 435 breast cancer patients. Only 20 healthy control individuals were included in the 
study, with the focus being on comparison of patients with Her2 amplified subtype (Her2+, n = 211) 
and those with triple negative breast cancer (TNBC, n = 224). Microarray data was normalized using 
miR-92a and miR-484, which were identified as relatively stable across arrays. However, there was 
no standardization of loading material, with RNA isolated from total EV yields and resuspended in 
the same volume for analysis. Indirect quantification of EVs in a subset of samples employing a 
CD63 ELISA (Her2+ (n = 78), TNBC (n = 40), and healthy controls (n = 10)) revealed a significant 
increase in EVs in both breast cancer groups compared to controls, with a higher (non-significant) 
level also reported in Her2+ compared to TNBC patients [19]. This is likely to have impacted the 
levels of miRNA detected. As our knowledge of EV characteristics and cargo continues to evolve, it 
is becoming increasingly important to standardize effective methods for analysis of the biomolecules 
within, and analysis of data generated. 
EV-specific miR-451a, analysed further in the current study, has previously been demonstrated 
to be elevated in the circulation of patients with non-small cell lung cancer [22] and to have potential 
applications in prognostication of patients with pancreatic ductal adenocarcinoma [23]. In this study 
we describe isolation of cell secreted EVs and circulating EVs in animal models and patients with 
breast cancer. This is followed by detailed EV characterisation. EV-miR-451a was quantified in the 
circulation of tumour-bearing animals, and breast cancer patients (n = 67) were compared to healthy 
control (n = 44) individuals. The HCC-1954 model is a HER2 amplified human breast cancer cell line, 
so was implanted into immunocompromised, athymic Balb/c mice. In the absence of an established 
EV-miRNA endogenous control or robust method for data normalization, absolute quantification of 
microRNA copy number is related to total EV number. 
2. Materials and Methods 
2.1. Culture of Breast Cancer Cell Lines 
HCC-1954-luc breast cancer cells were routinely maintained in RPMI-160. Media was 
supplemented with 10% FBS and 100 IU/mL penicillin G/100 µg/mL streptomycin sulphate 
(Pen/Strep). The cells were originally purchased from LGC limited and were authenticated every 
two years using single tandem repeat (STR) analysis. For bioluminescent in vivo imaging, 
HCC-1954-luc cells were previously transduced with lentivirus expressing a red-shifted Luciola 
Italica luciferase transgene, under the control of the Ubiquitin C (UbC) promoter (RediFect 
Red-FLUC-Puromycin Lentiviral particles, Perkin Elmer Maryland, USA) [24]. 
2.2. Patient Samples and Ethics 
All experimental procedures involving sera from human participants were approved by the 
Clinical Research Ethics Committee (University College Hospital, Galway). Written informed 
consent was obtained from each patient and all clinical investigation was performed according to the 
principles expressed in the Declaration of Helsinki [25]. A total of 111 female participants were 
enrolled for this study. This included 67 patients with breast cancer with a mean age of 55 (range 28–
84) and 44 healthy volunteers with a mean age of 50 (range 23–69; Table 1). Healthy control 
volunteers had no family history or a personal medical history of breast cancer. Volunteers deemed 
to have co-morbidities requiring active treatment were excluded from the study. Of the patients with 
breast cancer, 54 had the primary tumour in situ, while 13 had breast cancer metastasis following 
initial resection. Disease characteristics are detailed in Table 1. All serum samples were collected in 
Vacutainer Serum Separator Tubes II (Becton Dickinson), allowed to clot for 30 min, and centrifuged 
at 805× g at 4 °C for 10 min. Serum was then stored at −80 °C until required for EV isolation. 
Table 1. Clinicopathological characteristics of breast cancer patients from whom serum EVs were 
isolated. 
Healthy Volunteers  n = 44 Mean age (Range) 50 (23–69) 
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Breast Cancer Patients  n = 67 Mean age (Range) 55 (28–84) 
Histological Invasive type 
Ductal 
Lobular 
Other 
54 (80.5%) 
10 (14.9%) 
3 (4.4%) 
Epithelial Subtype 
Luminal A 
Luminal B 
HER2 
Basal 
42 (64.1%) 
9 (13.4) 
10 (14.9%) 
6 (8.9%) 
Nodal Status Node Positive Node Negative 
32 (47.7%) 
35 (52.2%) 
Tumour Grade 
1 
2 
3 
4 (5.9%) 
33 (49.2%) 
30 (44.7%) 
Stage (UICC) 
I 
II 
III 
IV 
13 (19.4%) 
29 (43.3%) 
11 (16.4%) 
14 (20.9%) 
2.3. In Vivo Breast Cancer Model 
Ethical approval for In Vivo studies was granted from the Animal Care Research Ethics 
Committee at the National University of Ireland Galway. Project authorisation was obtained from 
the Health Products Regulatory Authority (HPRA) of Ireland. 
Twenty-two female, athymic BALB/c nude mice (Charles River Laboratories Ltd. Kent, UK) 
aged 6–8 weeks were used in the study. All mice under anaesthetic (5% Isoflurane) received a 
mammary fat pad (MFP, second thoracic) injection of 3.5 × 106 HCC-1954-luc cells suspended in 200 
µL RPMI medium. All animals were drug naïve, had no previous procedures performed, and 
weighed between 18–20 g. Each animal’s environmental enrichment was monitored daily, including 
health and behaviour, cage conditions, food, and water. Cells were injected under sterile conditions 
on a surgical mount/heated stage. Disease progression was monitored using an in vivo imaging 
system (IVIS, PerkinElmer, Massachusetts, United States) following intraperitoneal (IP) injection of 
luciferin at 150 mg/kg. Approximately 6 weeks following tumour induction, animals were humanely 
sacrificed by cardiac puncture under isoflurane anaesthesia. Blood was harvested and serum was 
extracted from individual whole blood samples (not pooled) and stored at −80 °C until required for 
EV isolation. 
2.4. Isolation of EVs from Human/Murine Sera 
To isolate EVs from sera, 500 µL patient sera (n = 111) or animal sera (n = 22) was thawed and 
diluted in 12 mL PBS; that was followed by differential centrifugation at 800× g and 2000× g for 10 
min each, microfiltration (0.22 µm), and ultracentrifugation (Hitachi Koki himac, 
micro-ultracentrifuge CS150FNX; rotor S50A-2152) at 1.1×105× g for 120 min. EVs isolated from sera 
were re-suspended in sterile PBS and aliquoted for subsequent RNA isolation, protein analysis, NTA 
analysis, or TEM. Protein lysis solution (1% Triton X-100 in 20 mM Hepes, 2 mM EDTA, 150 mM 
NaCl, 10 mM sodium fluoride, 100X Protease Inhibitor Cocktail, and 2 mM sodium orthovanadate) 
was added to the samples destined for protein analysis. EVs were stored at −80 °C until required. 
2.5. Characterisation of Extracellular Vesicles 
To confirm the presence of EVs, morphological examination of fixed EVs embedded in resin 
was performed as previously described [26]. Briefly, a primary fixative (2% glutaraldehyde, 2% 
paraformaldehyde in a 0.1 M sodium cacodylate/HCL buffer, pH 7.2) was added to samples prior to 
ultracentrifugation, and following isolation, EVs were immersed in a secondary fixative (1% osmium 
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tetroxide), dehydrated in alcohol, and embedded in resin. Resin slices were then loaded onto a 
copper grid, stained, and viewed using an Hitachi H7000 transmission electron microscope [26]. 
Western blots were performed, targeting the EV-associated proteins CD81 (Abcam ab79559), 
CD82 (Abcam ab66400) and CD63 (Abcam ab68418). Protein concentration was determined by 
microBCA Assay (Pierce™, Thermo Fisher Scientific, Massachusetts, USA) according to 
manufacturer’s instructions. Protein samples (10 µg) were denatured for 10 min at 70 °C, which was 
followed by separation on a pre-cast Mini-PROTEAN® TGX™ Gel (Bio-Rad) for 60 min at 100 V. 
Protein molecular weight standards (20–220 kDa) were run simultaneously on each gel, followed by 
transfer to a nitrocellulose membrane. Once blots were blocked (5% milk in TBS-T for 1 h), each 
membrane was probed with an antibody targeting CD81 (1:1000 dilution, 1.5 h, RT), CD82, or CD63 
(both at 1:1000 dilution; overnight, 4 °C) diluted in 0.1% milk in TBS-T. Following a series of washing 
steps, a solution of secondary antibody (CD81—1:10,000; rabbit anti-mouse IgG HRP; Abcam 
ab6728; CD82 and CD63—1:3000; goat anti-rabbit IgG HRP; Abcam ab6721) was added to each 
membrane. Clarity™ Western ECL (Bio-Rad Laboratories, Maryland, USA) chemiluminescent 
substrate solution was applied to each membrane and blots were visualized using the Gel Doc™ 
XR+ and ChemiDoc™ XRS + Systems with Image Lab™ Software (Bio-Rad,version 5.2.1). 
Nanoparticle tracking analysis (NTA) (NanoSight NS500, Malvern Panalytical, UK) was used to 
analyse EV particle size distribution and concentration using a 405 nm laser source and EMCCD 
camera, running NTA software version 3.2 using optimised and validated protocols [27]. EV 
samples were diluted in PBS certified as particle-free by NTA (<3 particles per frame visible). 
Instrument calibration was verified daily using 100 nm polystyrene latex calibration nanoparticles 
(Malvern Panalytical). A total of five 60 s videos were recorded for each sample [27]. Total EVs per 
microliter were determined, along with quantification of those within 30–150 nm in size, 
representing the small EV (sEV) fraction. Spearman’s rank correlation coefficient was calculated to 
assess the relationship between total protein yield determined by microBCA assay, and number of 
EVs (total, and 30–150 nm size) was directly quantified by NTA. 
2.6. RNA Extraction and Absolute Quantitative (AQ)-PCR Analysis 
RNA was extracted from EV isolates (animal and patient sera) using the MagNA Pure Isolation 
(Roche) extraction process as per manufacturer’s instructions, and stored at −80 °C. MicroRNA 
(miR-451a) expression analysis was performed using TaqMan® assays and Universal Mastermix 
(Applied Biosystems) [28]. An inter-assay control was employed on each plate, and all samples were 
analysed in triplicate (standard deviation <0.3 required). Absolute quantification was used to 
determine the number of copies of miR-451a relative to a standard curve of known concentrations of 
synthetic miR-451a. Briefly, synthetic miRNA-451a (Applied Biosystems) was reconstituted in T/E 
buffer (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0) to generate a 2.38 × 10−4 mol stock solution. 
A working solution of 1 × 10−5 mol was produced and reverse transcription performed, as described 
previously [28]. Serial dilutions were prepared of standards ranging from 1 × 10−8 to 1 × 10−14 M. The 
comparative cycle threshold was used to calculate the quantity of miR-451a in samples relative to the 
standard curve generated [29,30]. The resultant value, obtained in moles, was converted to particles 
by multiplication through Avogadro’s constant (6.03 × 1023 particles) [31]. 
2.7. Statistical Analysis 
Continuous variables of interest are summarised numerically by means (with SEMs) and are 
graphically represented using boxplots. Shapiro–Wilk’s W test was employed to test the assumption 
of normality. Levene’s test was used to assess the equality of variances for a variable calculated for 
two or more groups. Comparisons of continuous parametric variables were performed using a 
Student’s t-test or ANOVA. Comparisons of non-parametric variables were performed using the 
Mann–Whitney test. The degree of relationship between pairs of response variables was assessed 
using the Pearson or Spearman correlation coefficient, as appropriate. A two-tailed p value of less 
than 0.05 indicated statistical significance. All analyses were performed using SPSS Version 22 (IBM 
Corporation, New York, NY, USA) and Minitab 17 (Minitab, Inc., Pennsylvania, USA). 
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3. Results 
3.1. Routine Characterisation of Isolated EVs 
To confirm the presence and assess the quantity of EVs isolated from sera, NTA, western 
blotting, and TEM were routinely performed, with representative images shown in Figure 1. Isolated 
EVs were characterised by NTA, which determined the number and size distribution, with the 
majority of vesicles falling within the size range of small EVs (sEVs), at 30–150 nm in size (Figure 
1A). Western blot analysis was performed, which confirmed that isolates expressed the 
EV-associated proteins CD81 (27–30 kDa), CD82 (60 kDa, n-glycosylated), and CD63 (50–60 kDa) at 
the appropriate band sizes (Figure 1B). EVs were visualized using TEM in both wide field (60,000×), 
showing multiple EVs of similar size and close field (120,000×) views, showing details of the lipid 
bilayer (Figure 1Ci,Cii). Vesicles of rounded morphology measuring 30–150 nm in diameter 
consistent with reported characteristics of sEVs were observed. 
 
Figure 1. Serum extracellular vesicle characterisation: (A) Nanoparticle tracking analysis—the mean 
size distribution and concentration (1 × 109) of the particles. The line represents the average of five 
readings with red shading showing range across readings; (B) western blot analysis confirming the 
detection of CD81 (27–30 kDa), CD82 (60 kDa), and CD63 (50–60 kDa) at the appropriate band sizes. 
(Ci) TEM wide field view image (60,000×) and (Cii) close field view (120,000×) demonstrating EVs 
with a round morphology and lipid bilayer. 
3.2. Quantifying EVs in Human Serum 
The total number of EV particles isolated from 500 µL sera as determined by NTA, ranged from 
3.42 × 108 to 8.90 × 1010/mL across all human serum samples (cancers and healthy controls, Table 2). 
The mean total number of EV particles was significantly higher in patients with breast cancer when 
compared to control serum samples (BrCa 1.85 × 1010 ± 1.99 × 109/mL versus control 1.18 × 1010 ± 1.42 × 
109/mL, Mann–Whitney U = 927.5, p = 0.001). 
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Table 2. Extracellular vesicle (EV) yield as determined by nanoparticle tacking analysis and protein 
yield as determined by microBCA assay from the sera of patients with breast cancer and healthy 
control individuals. 
Sample All EV Particles/mL 30–150 nm EV Particles/mL Protein Yield (µg/mL) 
Range Mean ± SEM Range Mean ± SEM Range Mean ± SEM 
All Sera (n = 111) 3.42 × 108–8.90 × 1010 1.59 × 1010 ± 1.36 × 109 1.26 × 108–5.73 × 1010 8.11 × 109 ± 8.60 × 108 70–1023 314 ± 20 
BrCa (n = 67) 3.42 × 108–8.90 × 1010 1.85 × 1010 ± 1.99 × 109 1.26 × 108–5.73 × 1010 9.30 × 109 ± 1.24 × 109 71–1023 345 ± 26 
Control (n = 44) 3.67 × 109–5.76 × 1010 1.18 × 1010 ± 1.42 × 109 1.15 × 109–4.49 × 1010 6.29 × 109 ± 1.02 × 109 70–935 268 ± 28 
Data relating to EVs in the size range associated with sEVs (30–150 nm) were then analysed. The 
number of EV particles of this size ranged from 1.26 × 108 to 5.73 × 1010/mL of serum for all samples. 
Similar to the analysis involving total EV particles, there was a significant increase of EV particles 
within this size range between the breast cancer patients and healthy volunteer individuals (9.30 × 
109 ± 1.24 × 109/mL versus 6.29 × 109 ± 1.01 × 109/mL, U = 1110.0, p = 0.028). Patients with breast cancer 
were further subdivided based on disease characteristics (outlined in Table 1) to determine whether 
there was any relationship between EV number and other disease characteristics, such as disease 
stage. No significant relationship was observed (e.g., disease stage UICC classification p = 0.869, 
Figure S1A). Although the highest number of EVs was detected in patients with metastatic disease (n 
= 13), this was not significantly higher than those with primary disease (n = 54), with both groups 
having a significant increase over healthy controls (Figure S1B). 
In relation to protein yield, despite a standardised volume of starting material, there was a wide 
range of protein quantity present across all human serum EV samples (n = 111, range 70.6–1023.3 
ng/µL), with no significant difference in sera from patients with breast cancer (345.2 ± 25.9 ng/µL) 
when compared to their healthy counterparts (268.1 ± 28.2 ng/µL, p = 0.053). In the past, protein yield 
has been widely used as a surrogate indicator of sEV quantity; however, as demonstrated in Figure 
2A, no relationship between sample total protein yield and number of exosomal EVs was detected 
(Spearman’s rho = 0.092, p = 0.339), with only a weak correlation with total EV yield detected (rho = 
0.216, p = 0.027, Figure 2B). 
 
Figure 2. Investigation of relationship between protein yield and number of EV particles quantified 
by NTA: No relationship was detected between (A) protein yield and small EV particles (30–150 nm, 
rho = 0.092, p = 0.339) with only a mild correlation between protein yield and total number of EV 
particles (B) detected (rho = 0.216, p = 0.027) in human serum samples. 
3.3. Detection of EV-miR451a in a Breast Tumour Bearing Murine Model 
EV-miR-451a was confirmed to be secreted by HCC-1954-luc cells in vitro, and then 
investigated in the serum EVs of HCC-1954-luc tumour bearing animals. Animals were treatment 
naïve prior to blood sampling, with no adverse events seen. As for the patient samples, murine 
serum EVs were quantified using NTA and protein yield was determined for the purposes of 
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western blot analysis (Figure 3A). Bioluminescent imaging (BLI) using IVIS provided quantitative 
data on tumour burden (relative light units, RLU, sample image shown in Figure 3B). 
 
Figure 3. (A) EV yield as determined by nanoparticle tacking analysis, and protein yield, as detected 
by microBCA assay from the sera of HCC-1954-luc tumour-bearing mice. (B) Sample bioluminescent 
IVIS image from a mouse bearing mammary fat pad tumour; (C) relationship between BLI (relative 
light units) and number of circulating EVs. 
MiR-451a was detected in all murine serum EV samples analysed (n = 22). Calculation of 
miR-451a copy number was determined by absolute quantification. A standard curve for 10−8 to 1 × 
10−14 mol dilutions of synthetic miR-451a was reproduced and a linear Equation (1) was accepted 
(Figure S 2A). An abundance of miRNA 451a was detected in the circulating EV particles of all breast 
cancer bearing murine models analysed (4.84 × 10−14–7.52 × 10−13 mol/mL). Applying Avogadro’s 
constant, the miR-451a copy number was calculated to range from 2.92 × 1010 to 4.54 × 1011 copies/mL 
(1 mol = 6.02 × 1023 particles). Although a small group (n = 22), preliminary analysis revealed a 
moderate correlation between serum EV number and tumour burden measured by BLI (rho = 0.386, 
p = 0.047, Figure 3C). 
y = −3.70 X–14.80. (1) 
3.4. EV-Encapsulated MiR-451a in Sera of Breast Cancer Patients and Healthy Controls 
A standard curve for 10−8 to 1 × 10−14 mol dilutions of synthetic miR-451a was reproduced and an 
average linear equation (Equation (2)) accepted (Figure S2B). After determining total number of 
miRNA-451a copies per sample by multiplication by Avogadro’s constant, total number of copies of 
miRNA-451a was expressed relative to the number of EVs in each sample. The mean number of 
copies of miRNA per EV ranged from 0.12 to 249.10 copies/EV. The mean number of miR-451a 
copies per EV was significantly greater in the patients with breast cancer in comparison to the 
healthy cohort (15.8 ± 4.4 versus 5.5 ± 1.7 copies, p = 0.029). A logarithm of the means was employed 
in Figure 4 to demonstrate this comparison. When expressed relative to the number of exosomal EVs 
(30–150 nm), a similar outcome was observed (38.60 ± 10.85 versus 11.63 ± 3.10 copies/EV, p = 0.019). 
Cells 2020, 9, 141 9 of 13 
 
When the breast cancer cohort were investigated in isolation, no relationship between disease stage 
and the mean number of miR-451a copies/EV was observed (5.58–24.44 copies/EV, ANOVA p = 
0.549). 
y = −3.24 X–11.31. (2) 
 
Figure 4. Number of miRNA-451a copies per EV particle in sera of breast cancer patients (n = 67) 
compared to healthy control individuals (n = 44, p = 0.029), o represents outlier 
4. Discussion 
Inter-laboratory reproducibility is crucial for EV-miRNAs to reach their potential as biomarkers 
or therapeutics. The data presented demonstrates that the previously widely used approach of 
indirectly quantifying EVs based on protein yield, bears no significant relationship with the number 
of EVs present in a sample when quantified directly using NTA. This was verified across patient 
serum samples and murine samples. Samples were isolated in two different laboratories to ensure 
sample collection method nor personnel were responsible, and NTA analysis was performed at a 
tertiary site, using ISO certified equipment. These findings have important implications for in vitro, 
in vivo, and clinical studies investigating the biomarker or therapeutic potentials of EVs. If samples 
are compared based on standardized protein yield, investigators may in fact be analysing the target 
(miRNA, protein, mRNA, etc.) in samples containing significantly different amounts of EV template. 
Therefore, elevated levels may be due to unintentional analysis of elevated EVs, rather than a 
clinically relevant increase in the analyte. Similarly, when testing the therapeutic potential of an EV 
population, it is imperative that equal amounts of EVs from different cell sources or with different 
modifications are loaded to ensure standardized comparison. This will also be critical for 
reproducibility in clinical trials. As the range of platforms available for particle analysis has 
increased due to market demand, with relative decreases in associated costs, access, and availability, 
research should be more widespread, allowing more teams to align with the MISEV guidelines in 
this area [12]. 
The choice of starting material (serum or plasma) tends to be most influenced by whichever 
sample type is routinely collected and accessible in the host lab. There is some concern that the 
clotting step in serum isolation will significantly deplete the EV fraction; however, there have been 
many studies successfully employing sera in breast and other cancer settings [1,4,5,16,32]. Equally 
there is concern that EVs isolated from plasma are coated with proteins and lipids likely to cause 
their aggregation and a potential loss upon centrifugation [33]. We have found serum to be a robust 
source of EVmiRs, as demonstrated in NTA analysis outlined previously, in agreement with other 
groups who reported plasma or sera as equally good sources of circulating EVs based on the 
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recovery, purity, morphology, and biological function [33]. There is no doubt that all sample sources 
present their own challenges, and robust characterisation of isolated EVs is an absolute requirement. 
The quantity of EVs released into circulation is a consequence of the site of origin, and these 
particles can envelope an extensive plethora of proteomic content. Taking ovarian cancer as an 
example, over 2000 species of protein have been identified from tumour-derived EVs, including 
many involved in disease progression and metastasis, such as membrane proteins, tetraspanins, and 
enzymes [34]. Serum samples were derived from cancer patients with different stages of disease and 
a range of disease burden as indicated in Table 1. Healthy control volunteers had no family history 
or a personal medical history of breast cancer; however, women of a variety of ages and 
backgrounds were included. While all patients satisfied the inclusion criteria for the study, factors 
that can impact protein content, such as excessive amounts of cells in the standardised starting 
volume, increased platelet activation, elevated immune and inflammatory response, and high 
concentrations of procoagulant and angiogenic agents were not accounted for [35]. Within the 
human sera analysed, a significantly higher quantity of EVs was observed in the cancer patients, 
compared to healthy controls. It is conceivable that a false increase in candidate miRNAs could then 
have been detected based on elevated EV template, highlighting the need for endogenous controls. 
Preliminary analysis also revealed a moderate correlation between tumour burden measured by BLI 
and the number of circulating EVs in murine sera (n = 22, rho = 0.386, p = 0.047). Cancer cells are 
believed to release more EVs into the circulation than normal cells [32,36,37], although it is important 
to note that the EVs come from a variety of cell sources and are representative of the host as much as 
the cancer. While direct quantification of EVs is important, robust and reliable protocols are also 
required, as inter-user variation has been shown to produce inaccurate results for both size and 
concentration measurements. This can be as high as 20% for size and 170% for concentration [38,39]. 
While NTA accuracy can also be hampered by the presence of co-purified EV contaminants, such as 
protein complexes and lipoproteins, this method does offer a means of direct quantification of EV 
number, which undoubtedly provides an improvement on indirect approaches [40]. 
EV quantification methods recently employed include NTA, tunable resistive pulse sensing 
(TRPS), vesicle flow cytometry, surface plasmon resonance, and electron microscopy [41]. While 
each have their merits, concordance across all must be questioned. A previously mentioned study 
reported elevated miR-1246 in plasma of a small cohort of breast cancer patients compared to 
healthy controls (n = 16 each) [17]. Zhai et al. [20] targeted the same miRNA in plasma using a novel, 
nucleic-acid-functionalized Au nanoflare probe. The probe enters EVs in plasma to generate a 
fluorescent signal by specifically targeting miR-1246, and was reported to discriminate between 
breast cancer (n = 46) and healthy control samples (n = 28) with 100% sensitivity and 92.9% specificity 
[20]. In the current study using miR-451a as an example, absolute quantification of the number of 
copies of the miRNA was performed and expressed relative to the number of EVs in each sample, as 
determined by NTA. A significant increase in miRNA-451a copies/EV was detected in sera of breast 
cancer patients (n = 67) compared to healthy controls (n = 44, p = 0.029), suggesting a role as a 
potential novel biomarker of breast cancer. While the authors do not suggest that miRNA copy 
numbers are evenly dispersed in each EV, this provides an approach that takes into account the 
number of EVs present in each sample. This could be impacted by a myriad of patient factors, 
including tumour burden, host immune response to disease or to therapy, and other co-morbidities, 
all of which will then impact the data generated. 
5. Conclusions 
It is clear that EV source, isolation, and characterization methods; data normalization and 
analysis; and reporting of study parameters, are heterogeneous in the published literature. If we do 
not address the controversies faced by this rapidly evolving field, there is a danger that the true 
potential of EVs may not be fully realized. It is imperative to address these issues and perform 
appropriately powered studies, using clinically relevant models of disease, patient samples that 
represent the heterogeneity of breast cancer and appropriately matched controls, taking into account 
the impact of standard clinical interventions, and immune response to disease. Multidisciplinary 
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collaboration will be key to realizing the immense potential of EV-miRNAs as robust, clinically 
relevant biomarkers of disease. 
Supplementary Materials: The following are available online at www.mdpi.com/2073-4409/9/1/141/s1. Figure 
S1: (A) Investigation of relationship between circulating EV number and disease stage (B) Circulating EV 
number in healthy control individuals compared to breast cancer patients with primary tumours in situ and 
those with metastases present. Figure S2: A standard curve for 1 × 10−8 to 1 × 10−14 mol dilutions of synthetic 
miR-451a was reproduced, and a linear equation (A) (y = -3.70(×)–14.80) for the murine study and (B) (y = -3.24 
(×)–11.31) for human sample analysis was accepted. 
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